# Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026*

## What topics and trends defined most-cited Estrogen and related hormone effects research in the Class of 2026?

Research in the Class of 2026 centers on menopausal hormone therapy and targeted breast cancer care. Menopause and coronary heart disease risk saw major increases, while estradiol and selective estrogen receptor degraders gained momentum. Conversely, traditional aromatase inhibitors declined sharply as attention shifted toward novel combination therapies and precision cardiometabolic risk management.

## At a glance

| Fact | Value |
| --- | --- |
| Field | Estrogen and related hormone effects |
| Cohort label | Class of 2026 (2024 publications) |
| Papers analyzed | 2,723 |
| Papers ranked | 20 |
| Top topics in ranked papers | Menopause, menopausal hormone therapy, advanced breast cancer, CDK4/6 inhibitors, SERDs |
| Publication window | Jan 1, 2024 – Dec 31, 2024 |
| Eligibility | Research articles; reviews excluded |
| Citation window | 18 months post-publication |
| 18m citation range | 25–70 |
| Data source | OpenAlex · Retrieved Jul 2026 |
| License | CC BY 4.0 |

## Rankings

| Rank | Title | Authors | Corresponding authors | Affiliation | Journal | 18m citations | DOI |
| ---: | --- | --- | --- | --- | --- | ---: | --- |
| 1 | Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause | JoAnn V Pinkerton, James A Simon, Hadine Joffe, Pauline M Maki, Rossella E Nappi, Nick Panay, Claudio N Soares, Rebecca C Thurston, Cecilia Caetano, Claudia Haberland, Nazanin Haseli Mashhadi, Ulrike Krahn, Uwe Mellinger, Susanne Parke, Christian Seitz, Lineke Zuurman | JoAnn V. Pinkerton | University of Virginia Health, United States | JAMA | 70 | 10.1001/jama.2024.14618 |
| 2 | Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial | Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Vladimir Vladimirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Ajimi, Bistra Kirova, Teresa Klinowska, Justin P O Lindemann, Delphine Lissa, Alastair Mathewson, Christopher J Morrow, Zuzana Traugottova, Ruaan van Zyl, Ekaterine Arkania | Mafalda Oliveira | Vall d'Hebron Institute of Oncology, Spain | The Lancet Oncology | 70 | 10.1016/s1470-2045(24)00387-5 |
| 3 | An empowerment model for managing menopause | Martha Hickey, Andrea Z LaCroix, Jennifer Doust, Gita D Mishra, Muthusamy Sivakami, Deborah Garlick, Myra S Hunter | Martha Hickey | University of Melbourne, Australia | The Lancet | 66 | 10.1016/s0140-6736(23)02799-x |
| 4 | Elacestrant in ER+, HER2− Metastatic Breast Cancer with <i>ESR1</i> -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups | Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O'Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani | Aditya Bardia | University of California Los Angeles, United States | Clinical Cancer Research | 64 | 10.1158/1078-0432.ccr-24-1073 |
| 5 | Menopausal Hormone Therapy Use Among Postmenopausal Women | Lin Yang, Adetunji T Toriola | Lin Yang, Adetunji T. Toriola | Alberta Health Services, Canada | JAMA Health Forum | 60 | 10.1001/jamahealthforum.2024.3128 |
| 6 | Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause | Celine Camon, Michael Garratt, Stephanie M Correa | Michael Garratt, Stephanie M. Correa | University of Otago, New Zealand | Nature Aging | 53 | 10.1038/s43587-024-00767-0 |
| 7 | Hallmarks of female reproductive aging in physiologic aging mice | Julia L Balough, Shweta S Dipali, Karen Velez, T Rajendra Kumar, Francesca E Duncan | Francesca E. Duncan | Buck Institute for Research on Aging, United States | Nature Aging | 51 | 10.1038/s43587-024-00769-y |
| 8 | Estrogen and cardiovascular disease | Felice Gersh, James H O'Keefe, Andrew Elagizi, Carl J Lavie, Jari A Laukkanen | Felice L Gersh | University of Arizona, United States | Progress in Cardiovascular Diseases | 46 | 10.1016/j.pcad.2024.01.015 |
| 9 | In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology | Lisa Mosconi, Matilde Nerattini, Dawn C Matthews, Steven Jett, Caroline Andy, Schantel Williams, Camila Boneu Yepez, Camila Zarate, Caroline Carlton, Francesca Fauci, Trisha Ajila, Silky Pahlajani, Randolph Andrews, Alberto Pupi, Douglas Ballon, James Kelly, Joseph R Osborne, Sadek Nehmeh, Matthew Fink, Valentina Berti, Jonathan P Dyke, Roberta Diaz Brinton | Lisa Mosconi | Weill Cornell Medicine, United States | Scientific Reports | 46 | 10.1038/s41598-024-62820-7 |
| 10 | Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial | Therese Johansson, Torgny Karlsson, Dana Bliuc, Daniel Schmitz, Weronica E Ek, Alkistis Skalkidou, Jacqueline R Center, Åsa Johansson | Therese Johansson | Uppsala University, Sweden | BMJ | 43 | 10.1136/bmj-2023-078784 |
| 11 | Menopause transition and cardiovascular disease risk | Erin R Uddenberg, Nancy Safwan, Mariam Saadedine, Maria D Hurtado, Stephanie S Faubion, Chrisandra L Shufelt | Chrisandra Shufelt | Mayo Clinic, United States | Maturitas | 39 | 10.1016/j.maturitas.2024.107974 |
| 12 | Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial | Mafalda Oliveira, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, Masakazu Toi, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Zbigniew Nowecki, Yeon Hee Park, Joo Hyuk Sohn, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Marta Fulford, Haylee Andrews, Ian Wadsworth, Celina D'Cruz, Nicholas C Turner, CAPItello-291 study group | Mafalda Oliveira | Vall d'Hebron University Hospital, Spain | The Lancet Oncology | 36 | 10.1016/s1470-2045(24)00373-5 |
| 13 | Assessing male reproductive toxicity of environmental pollutant di-ethylhexyl phthalate with network toxicology and molecular docking strategy | Yanggang Hong, Yi Wang, Deqi Wang, Qichao Yuan, Zihan Yang, Chuncao Deng | Yanggang Hong | Wenzhou Medical University, China | Reproductive Toxicology | 35 | 10.1016/j.reprotox.2024.108749 |
| 14 | Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study | Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joohyuk Sohn, acelERA Breast Cancer Study Investigators | Miguel Martín | Hospital Gregorio Marañón, Spain | Journal of Clinical Oncology | 33 | 10.1200/jco.23.01500 |
| 15 | A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results | E Hamilton, M Oliveira, N Turner, J García-Corbacho, C Hernando, E M Ciruelos, P Kabos, M Ruiz-Borrego, A Armstrong, M R Patel, C Vaklavas, C Twelves, V Boni, J Incorvati, T Brier, L Gibbons, T Klinowska, J P O Lindemann, C J Morrow, A Sykes, R D Baird | Richard D. Baird | Sarah Cannon Research Institute, United States | Annals of Oncology | 29 | 10.1016/j.annonc.2024.04.012 |
| 16 | Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial | Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A O'Shaughnessy, Stephen Johnston, Adam Brufsky, Wayne D Tilley, Beth Overmoyer | Carlo Palmieri | The University of Liverpool, United Kingdom | The Lancet Oncology | 29 | 10.1016/s1470-2045(24)00004-4 |
| 17 | Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer | M T Herrera-Abreu, J Guan, U Khalid, J Ning, M R Costa, J Chan, Q Li, J-P Fortin, W R Wong, P Perampalam, A Biton, W Sandoval, J Vijay, M Hafner, R Cutts, G Wilson, J Frankum, T I Roumeliotis, J Alexander, O Hickman, R Brough, S Haider, J Choudhary, C J Lord, A Swain, C Metcalfe, N C Turner | Ciara Metcalfe, Nicholas C. Turner | The Institute of Cancer Research, United Kingdom | Nature Communications | 28 | 10.1038/s41467-024-53837-7 |
| 18 | Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses | Seo H Baik, Fitsum Baye, Clement J McDonald | Seo Hyon Baik | US National Institutes of Health, United States | Menopause The Journal of The North American Menopause Society | 26 | 10.1097/gme.0000000000002335 |
| 19 | Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer | Nusrat Jan, Shazia Sofi, Adel Abo Mansoor, Adil Abdelrahim, Irshad Ahmad, Abdullah Almilabairy, Fuzail Ahmad, Manzoor Ahmad Mir | Manzoor Ahmad Mir | University of Kashmir, India | Frontiers in Pharmacology | 26 | 10.3389/fphar.2024.1361679 |
| 20 | Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer | Stephanie W Vrede, Willem Jan Van Weelden, Johan Bulten, C Blake Gilks, Steven Teerenstra, Jutta Huvila, Xavier Matias-Guiu, Antonio Gil-Moreno, Jasmin Asberger, Sanne Sweegers, Louis J M van der Putten, Heidi V N Küsters-Vandevelde, Casper Reijnen, Eva Colas, Jitka Hausnerová, Vit Weinberger, Marc P L M Snijders, Petra Vinklerova, Antonella Ravaggi, Franco Odicino, Eliana Bignotti, Jessica N McAlpine, Roy Kruitwagen, Johanna M A Pijnenborg | Stephanie Vrede | Radboud University Medical Center, Netherlands | Gynecologic Oncology | 25 | 10.1016/j.ygyno.2024.10.028 |

## Topic trends

### What Topics Define the Class of 2026?

The Class of 2026 cohort in estrogen and related hormone research is driven by two major pillars: postmenopausal hormone therapy alongside women's cardiometabolic health, and targeted therapeutic strategies for hormone receptor-positive (HR+) advanced breast cancer.

Menopause and menopausal hormone therapy (MHT) dominate the landscape, appearing in 28% and 18% of top-ranked publications respectively. High-impact investigations focus on clarifying long-term cardiovascular risks, cognitive function, and individual risk-benefit profiles associated with systemic MHT and estrogen monotherapy. Estradiol signaling and sex hormone-binding globulin (SHBG) emerge as key physiological biomarkers for metabolic and endocrine assessment in aging populations.

In parallel, oncology research centers heavily on targeted interventions for advanced and HER2-negative breast cancer. Selective estrogen receptor degraders (SERDs), such as fulvestrant and novel oral agents, along with CDK4/6 inhibitors remain central clinical focal points. Studies evaluate combination regimens aimed at overcoming endocrine resistance, managing hot flashes, and tailoring risk stratifications for estrogen receptor-positive disease.

Together, these focal points reflect a dual clinical focus: optimizing long-term systemic hormone safety during menopausal transitions while refining endocrine and targeted therapies for estrogen-driven malignancies.

*Leading research themes*

### How Did Topics Shift from the Class of 2025 to the Class of 2026?

Comparing the Class of 2025 to the Class of 2026 reveals significant thematic shifts in estrogen research, characterized by a surging interest in postmenopausal health outcomes and a strategic pivot in oncology therapeutics.

The most prominent growth occurred in menopausal hormone therapy and postmenopausal risk assessment. Menopause research rose by 10 percentage points (from 18% to 28%), while coronary heart disease emerged sharply as a major focal area (reaching 10% of ranked literature from zero in the previous cohort). Estradiol evaluation (+6 percentage points) and breast cancer risk modeling (+8 percentage points) also recorded strong upward momentum, driven by large-scale clinical trials and colocalization analyses examining systemic hormone exposure.

Conversely, traditional monotherapies and older treatment frameworks experienced noticeable declines. Aromatase inhibitors saw the steepest drop, falling from 18% in 2025 down to 6% in 2026 (-12 percentage points), reflecting a transition toward next-generation combination therapies. Generic hormone receptor-positive breast cancer classifications also contracted as studies adopted more granular molecular subtyping, such as HER2-negative and ESR1-mutated designations.

These shifts highlight a field broadening its scope beyond localized tumor suppression toward comprehensive cardiovascular risk management, precision risk stratification, and novel SERD-based therapeutic regimens.

*How topics shifted year over year*

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```